Saturday, 23 September 2017
Latest news
Main » Stock to Track: Arrowhead Pharma (ARWR)

Stock to Track: Arrowhead Pharma (ARWR)

17 September 2017

Two analysts have provided estimates for Arrowhead Pharmaceuticals' earnings, with the lowest EPS estimate coming in at ($0.18) and the highest estimate coming in at ($0.10).

Arrowhead Pharmaceuticals, Inc. (ARWR) has an Analysts' Mean Recommendation of 3. The company is expected to announce its next earnings results on Wednesday, December 13th.

Arrowhead Pharmaceuticals, Inc. on 6/29/2017 reported its EPS as $-0.34 with the analysts projecting the EPS of the stock as $-0.2.

More news: Arsene Wenger Unconcerned By Arsenal's Stamford Bridge Struggles

EPS Estimate for the next Quarter is -0.1. One investment analyst has rated the stock with a sell rating and five have given a hold rating to the stock.

P/E of the company is not reported. Arrowhead Pharmaceuticals had a negative return on equity of 46.73% and a negative net margin of 201.84%. Company's stock ranged between $2.65 and $3.53 during the previous session. Shares are clocking price at $2.79 with change of -20.96%. Finally, Jefferies Group LLC restated a "hold" rating and set a $2.00 target price on shares of Arrowhead Pharmaceuticals in a report on Friday, August 4th. Earnings surprises can have a huge impact on a company's stock price. Cantor Fitzgerald reiterated a hold rating and issued a $2.00 price objective (up from $1.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday.

Return on Assets (ROA) ratio indicates how profitable a company is relative to its total assets. Teachers Advisors LLC increased its position in shares of Arrowhead Pharmaceuticals by 18.0% during the fourth quarter. Virtu KCG Holdings LLC boosted its position in shares of Arrowhead Pharmaceuticals by 115.6% in the 2nd quarter. The stock volatility for week was 16.38% while for month was 11.62%. Wells Fargo & Company MN now owns 150,346 shares of the biotechnology company's stock worth $278,000 after purchasing an additional 88,933 shares during the period. Finally, SG Americas Securities LLC increased its position in shares of Arrowhead Pharmaceuticals by 287.9% during the first quarter. Teachers Advisors LLC now owns 112,642 shares of the biotechnology company's stock worth $175,000 after purchasing an additional 17,201 shares during the last quarter.

More news: Options for North Korea are 'effective and overwhelming'

Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments. If you are accessing this news story on another website, it was copied illegally and republished in violation of USA and worldwide trademark and copyright law. If you are reading this story on another domain, it was illegally copied and reposted in violation of USA & global copyright law. When we divide the last trade volume by the 3-month average volume, we found out a relative volume of 3.27. Short-term traders are predicted to see a rally of 86.21% over the course of a quarter and, with 90% chance the price will be floating in the range of $4.43 and $6.63 in this timeframe. A total volume of 3.57 million shares were traded versus to average volume of 1.09 million shares. The company's market cap is $207.87 million.

Taking a broader look at the analyst consensus, according to 4 analysts Arrowhead Pharma (NASDAQ:ARWR)'s price will reach at $1.5 during 52 weeks. ARWR's latest closing price was 50.34% away from the average-price of 200 days while it maintained a distance of 32.48% from the 50 Day Moving Average and 2.59% away compared to its SMA 20.

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, launched on February 13, 2001, develops medicines that treat intractable diseases by silencing the genes that cause them.

More news: UN Security Council to hold emergency meeting on DPRK's latest missile launch

Stock to Track: Arrowhead Pharma (ARWR)